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Abstract 
Background 
Lentigo maligna (LM) is an in-situ form of melanoma carrying a risk of progression to invasive 
lentigo maligna melanoma (LMM). LM poses a clinical challenge, with subclinical extension and 
high recurrence rates after incomplete surgery. Alternative treatment methods have been 
investigated with varying results. Photodynamic therapy (PDT) with methylaminolaevulinate 
(MAL) has already proved promising in this respect. 
Objectives 
To investigate the efficacy of ablative fractional laser (AFL)-assisted PDT with 5-aminolaevulinic 
acid nanoemulsion (BF-200 ALA) for treating LM. 
Methods 
In this non-sponsored, prospective pilot study ten histologically verified LMs were treated with 
AFL-assisted PDT three times at two week intervals using a light dose of 90 J/cm2 per treatment 
session. Local anaesthesia with ropivacain was used. Four weeks after the last PDT treatment the 
lesions were treated surgically with a wide excision and sent for histopathological examination. The 
primary outcome was complete histopathological clearance of the LM from the surgical specimen. 
Patient-reported pain during illumination and the severity of the skin reaction after the PDT 
treatments were monitored as secondary outcomes. 
Results 
The complete histopathological clearance rate was 7 out of 10 LMs (70%). The pain during 
illumination was tolerable, with the mean pain scores for the PDT sessions on a visual assessment 
scale ranging from 2.9 to 3.8. Some severe skin reactions occurred during the treatment period, 
however.  
Conclusions 
AFL-assisted PDT showed moderate efficacy in terms of histological clearance. It could constitute 
an alternative treatment for lentigo maligna but due to the side-effects it should only be considered 
in inoperable cases.  
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Introduction 
 
Lentigo maligna (LM) is the most common subtype of melanoma in-situ.1,2 It occurs on the 
chronically sun-damaged skin of elderly patients, typically in the head and neck region.3,4 If left 
untreated, it can progress to invasive lentigo maligna melanoma (LMM) with an estimated lifetime 
risk of 5–50%.5,6. Due to the ageing population and high UV exposure, the incidence of LM and 
LMM is steadily increasing in Europe, the U.S.A. and Australia.2,7-10 LMM now encompasses 4–
15% of all invasive melanomas.11 
 
The gold standard treatment for LM is wide surgical excision with 5–10 mm peripheral margins.3 
Staged excision and Mohs micrographic surgery can be used to improve margin control and to 
strive for lower recurrence rates.12 Due to the size and location of the LM and the age of the patient, 
surgery may sometimes be inappropriate or contraindicated, however.13 Alternative, non-surgical 
treatment modalities that have been investigated with varying results in terms of recurrence rates 
include cryotherapy, radiotherapy, Grenz ray therapy, topical imiquimod and photodynamic therapy 
(PDT).12,14,15 Karam et al. reported in a retrospective study that PDT with methylaminolaevulinate 
(MAL) achieved complete clearance in 12/15 cases,15 although admittedly only parts of the lesions 
were examined histologically for possible recurrence. 
 
Clinically it can be difficult to distinguish between LM and LMM.11 A novel imaging method 
employing a hyperspectral camera (HSC) can be used to delineate LM margins and detect dermal 
invasion.16,17  
 
The aim of this prospective pilot study was to investigate whether ablative fractional laser-assisted 
photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) is effective for 
treating lentigo maligna. 
 
Materials and methods 
 
Study design 
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The protocol for this non-sponsored, prospective pilot study complied with the Declaration of 
Helsinki and was approved by the local ethics committee of Tampere University Hospital. Informed 
written consent was obtained from all the participants. 
 
Participants 
 
Voluntary patients with a clinical suspicion of LM were enrolled from among those referred to the 
Department of Dermatology at Päijät-Häme Central Hospital, Lahti, Finland, between February 
2016 and December 2017. Both male and female subjects aged over 18 years with a biopsy-proven 
LM located on the face, neck or upper body were included in the series. Exclusion criteria were: i) 
histologically verified invasive LMM, ii) porphyria or photosensitivity, iii) allergy to 
photosensitizer and iv) pregnancy or breastfeeding. 
 
Treatment procedure 
 
A flow-chart of the study is presented in Figure 1. During the first study visit the suspected LM was 
examined clinically with a dermatoscope (Dermlite® DL3, 3Gen, California, U.S.A.) and under 
Wood’s light (Burton®), in order to help define the clinical borders.18 These borders were then 
traced on a transparent plastic sheet and photographed. The lesions were also imaged with a 
hyperspectral camera, prototype HSCP2 (Revenio Group, Vantaa, Finland), in order to reveal 
possible invasion and to provide a guide to the biopsy site.17 
 
A 3 mm punch biopsy was taken from the darkest part of the lesion and/or from the most clearly 
emphasized area by HIS to confirm the histological diagnosis and to rule out invasion. The 
histopathological evaluations of the diagnostic samples were conducted by an experienced 
dermatopathologist (L.J.) who received the samples without any background information other than 
the location of the lesion. Only patients with a biopsy-proven LM without any invasive component 
were included in the series from this point in the protocol onwards. 
 
The histologically confirmed LMs were treated with PDT three times at two week intervals, 
employing the following procedure. First, a 5 mm margin was drawn around the lesion and the area 
was anaesthetized with a local anaesthetic (Ropivacain Fresenius Kabi 7.5mg/ml, Fresenius Kabi 
AS, Halden, Norway). The area was then pre-treated with an ablative fractional CO2 laser (DS-
40UB Multixel, Daeshin Enterprise Co., Seoul, South Korea) to enhance the absorption of the 
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photosensitizer precursor. The laser settings were: Density level=5, Depth level=7 and Pulse 
duration=700ms, which correspond to a distance of 0.8 mm between the laser pores on the grid and 
a calculated pulse energy of 84mJ per pore. After the pre-treatment a 1mm-thick layer of 
photosensitizer precursor, 5-aminolevulinic acid nanoemulsion gel, BF-200 ALA,78 mg/g 
(Ameluz®, Biofrontera AG, Leverkusen, Germany), was applied to the skin over the whole 
treatment area, including the margins, and occluded under a light impermeable cover for three 
hours. Finally, the treatment area was illuminated with an Aktilite® CL128 lamp (Galderma Nordic 
AB, Uppsala, Sweden) at a light dose of 90J/cm2. 
Four weeks after the last PDT treatment the lesions were excised surgically together with a 5 mm 
margin by the investigator M.G. and sent for routine histopathological examination. The lesion 
borders and margins were defined with the help of the pre-treatment plastic sheets.  
The specimens were fixed in 4% formalin, embedded in paraffin, sectioned using the traditional 
vertical bread loaf technique and stained with haematoxylin-eosin (H&E). Immunohistochemistry 
(MART1/Melan A) was used as an aid to diagnosis where necessary. 
Efficacy assessment 
The primary outcome was complete histopathological clearance of the LM from the surgical 
specimen. For this purpose the excision specimens were evaluated by an experienced 
dermatopathologist (L.J.), who received the samples without any background information. The 
diagnosis was mainly based on routine staining with H&E, with additional immunohistochemical 
staining (MART-1/MelanA) if needed. The LM was considered to be histologically cleared if no 
sign or suspicion of atypical melanocytes could be seen, and uncured if the histological criteria for 
LM were still fulfilled or if there was any suspicion of atypical melanocyte proliferation. 
Safety and tolerability assessment 
The declared secondary outcomes of the study were pain during the PDT illumination, the severity 
of the skin reaction two days after the first PDT treatment, and the severity of delayed skin reactions 
after all the PDT sessions. The patients filled in visual analogue scales for pain (VAS 0–10) i) 
before the LED lamp illumination, ii) one minute after the start of the illumination, ii) in the middle 
and iv) at the end. To evaluate the local skin reactions (erythema, crusting, swelling), a nurse 
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photographed the treatment area two days after the first PDT treatment and the investigator J.E.R. 
assessed the severity of the skin reaction from photographs on a scale of 1–4 (1 negligible; 2 mild; 3 
moderate; 4 severe). Delayed inflammatory skin reactions were also evaluated during the second 
and third PDT treatments by J.E.R. or M.G., in addition to which the patients were asked to report 
any intense or unexpected skin reactions after any of the DT sessions. 
 
Sample size 
 
The exact optimal sample size could not be calculated for this pilot study due to a lack of previous 
research data. We were aiming at a sample size of 10–15 LM lesions. 
 
Results 
 
Baseline characteristics 
 
Altogether 24 patients with a total of 32 lesions were enrolled. Of these, 11 lesions were verified as 
LM and were included in the study. Three lesions were verified as invasive LMM, and 18 lesions as 
other pigmented lesions not fulfilling the criteria for LM and were thus excluded (Fig. 1). 
Furthermore, one LM was excluded after biopsy because of difficulties in scheduling the PDT 
treatments according to the study protocol. Thus, altogether 10 LMs in 9 patients (one patient had 
two LMs) completed the study.  
 
The patient demographics and the baseline characteristics of the LM lesions are presented in Table 
1. None of the patients had received previous treatment (e.g. cryotherapy, surgery, PDT) in the skin 
areas where the LMs were located. The mean ± SD (standard deviation) area of a LM lesion was 98 
± 58 mm2. 
 
Primary outcome: Histopathological clearance 
 
Seven out of the ten lesions (70%) were histologically completely cleared from the wide excision 
specimens, whereas the histology of three lesions demonstrated a residual LM. Example 
photographs and histological images of one cured and one uncured LM are shown in Figures 2 and 
3. Details of the clinical response, dermoscopy and histological clearance of the LM lesions are 
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presented in Table 2. Of note, the numbering of the LM lesions (1–10) is uniform in Tables 1 and 2 
so that the data can be compared between the tables. In two of the three uncured lesions there was 
some visible and clinically detectable pigmentation left after the treatments, so that a residual was 
suspected. Interestingly, one uncured lesion had no visible pigmentation to be seen, so that it was 
apparently clinically cleared. In the histologically cleared lesions there was either no visible 
pigmentation left (4 lesions) or the pigmentation was almost invisible, with only a small area left (3 
lesions). 
 
Secondary outcomes: safety and tolerability 
 
The pain VAS scores during the PDT illumination and the skin reactions two days after the first 
PDT are shown in Table 3. The maximal patient-reported pain was scored as moderate, and the 
highest VAS scores were reported during the second PDT session. The skin reaction was severe 
(swelling, pustules, intense erythema, crusting) in four LM lesions, moderate (marked erythema, 
crusting) in five and mild (mild erythema, scaling) in one. The delayed skin reaction two weeks 
after the first and second PDTs (assessed immediately before the second and third PDT treatments) 
was moderate in two patients, mild in five patients and negligible in two. Furthermore some 
unexpected adverse effects occurred after the PDT treatment (Table 3). Two patients experienced 
moderate pain for several hours after the second PDT session, one patient had a very intense skin 
reaction and one displayed swelling of the skin of the eyelid and neck. Likewise one patient 
experienced intense swelling, erythema and burning pain which led to a hospital visit on the day 
after the third PDT session. One patient suffered a continuous stinging pain in the excision area for 
four weeks after surgery, but it ceased after a second excision to increase the margins. Four weeks 
after the last PDT session (i.e. just before the excision) the following long-term adverse reactions of 
the treatment area were seen: postinflammatory erythema in five lesions, mild hypopigmentation in 
three lesions and mild hyperpigmentation in three lesions. None of the patients expressed visible 
scarring in the treatment area. 
 
Discussion 
 
This pilot study is to our knowledge the first prospective trial to investigate the efficacy of AFL-
assisted PDT for treating lentigo maligna. The histological clearance rate appeared to be moderate, 
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seven out of ten LM lesions (70%) after three PDT sessions, but the treatment caused side effects 
and should only be considered in inoperable cases. 
 
In an earlier retrospective study reported by Karam et al. 15 LM lesions were treated with PDT, 
resulting in a cure rate of 12/15 (80%).15 Methylaminolaevulinate (MAL) was used as a 
photosensitizer, but the light dose and the number of PDT sessions varied among the patients (in the 
ranges 40–90 J/cm² and 3–9 sessions). It is worth noting, however, that the clearance of LMs was 
assessed by clinical follow-up after variable lengths of time (18–50 months), and by means of 
histological examinations of multiple biopsies rather than wide excisions, which may have resulted 
in missed histological residuals. In our present study the lesions were excised completely after PDT 
for a full histopathological evaluation.  
 
The gold standard treatment of LM is wide surgical excision which is also recommended by the 
current treatment consensus. However, the surgery is not always easily applicable for example if the 
LM lesion is large and in esthetically difficult location, or if anesthesia is contraindicated, or if the 
patient simply refuses the surgery. In these cases the alternative treatment options like AFL-assisted 
PDT could still be used. The follow-up for a possible recurrence of LM should be arranged in all 
non-surgical alternative therapies. It should be noted, that clinical follow-up of LM alone after PDT 
involves a risk that a residual could be missed. This danger exists because, even though the 
treatment may destroy all the visible pigment, a histological examination can still reveal a residual 
LM. This was the case in one of the three residual cases found here. For this reason a follow-up 
with histological verification is to be recommended even though the lesion may become clinically 
unpigmented and thus appear to be cured. We would suggest punch biopsies of the lesion in the 
follow-up visits taken from the previously visible center of the lesion or any visible pigmentation. 
 
It is not known what is a sufficient PDT light dose for treating melanocytic lesions. When treating 
non-melanocytic lesions the photobleaching of PpIX is maximal in the initial phase of light 
illumination (more than 70% of PpIX is activated during the first 10 J/cm²) but the photobleaching 
continues slowly until the completion of the standard dose 37 J/cm².19 There is no earlier data 
available for the photobleaching of PpIX in melanocytic tumours but we assumed that it occurs in 
slower rate especially in the deeper situated melanocytes because melanin absorbs a portion of the 
red wavelength light. Karam et al. used higher doses of 40–90 J/cm² (on average 60 J/cm²) than for 
the treatment of non-melanoma skin cancers (37 J/cm²), justifying this by the fact that melanin 
restricts the diffusion of red light into the deep layers of the epidermis.15 In the present pilot study 
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we used an experimental dose of 90 J/cm² to ensure that almost all PpIX is activated also in the 
deeper parts of the tumour during the slow gradual photobleaching after the rapid initial phase. This 
was partly because we didn’t want the efficacy of the PDT to be hindered due to unoptimal PDT 
protocol. The higher light dose lengthens the illumination time (approximately 18 min for 90 J/cm2) 
but causes no other disadvantage for the patient. Probably a smaller light dose would also suffice, 
but to confirm this further investigations are warranted with measurement of the BF-200 ALA-
induced fluorescence in LM lesions during illumination. 
 
The mean patient-reported pain during PDT illumination remained low in our study, ranging from 
2.9 to 3.8 on the VAS scale (0–10). The highest average pain was experienced during the second 
PDT session and the maximum pain VAS value reported was 6.5. In the present instance the 
lesional skin was injected with a local anaesthetic (ropivacaine) 3 hours before illumination to 
reduce the pain to a more bearable level, taking into account the longer skin illumination time of 
approx. 18 min. For four out of the 10 patients the first PDT treatment provoked a severe skin 
reaction two days after the session. The reaction subsided within two weeks, i.e. before the second 
PDT session. In two patients an intense skin reaction also occurred after the second PDT session, 
and in one patient a very severe reaction was seen after the third PDT. The reactions were definitely 
more severe than those reported in PDT of non-melanocytic skin cancers.20,21 We assume that the 
stronger reactions were caused by the pre-treatment with AFL combined with the high light dose of 
90 J/cm² used. The increased amounts of inflammatory cells and cytokines in the lesional skin 
following the first PDT might explain why the most severe side-effects were seen in relation to the 
second session. 
 
The histopathological evaluation of the present excision specimens showed dermal scars in 5/10 
lesions after PDT, which could be due to the earlier biopsies or to the AFL pre-treatment and not be 
actual reactions to the treatment. Before excision, no visible scarring could be seen in the treatment 
area for any of the ten LM lesions. 
 
When treating LM non-surgically, one should note the growth of atypical melanocytes down the 
follicular units.22 In a histopathological review of 100 patients such follicular growth was seen in 
95% of LMs, with a mean depth of 0.45 mm (range 0.1–1.1 mm).23 For topical therapy to succeed, 
the topical agent such as the photosensitizer precursor should penetrate deep enough into the skin to 
reach all the atypical melanocytes, down to the deepest part. To ensure this and to enhance the 
efficacy of PDT, we considered it important to use ablative fractional CO2-laser pre-treatment 
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which increases the uptake and deep penetration of ALA and MAL into the skin.24 AFL pre-
treatment has been shown earlier to enhance the clinical efficacy of PDT when treating non-
melanoma skin cancer.25-27 The photosensitizer distribution in the deeper layers of the skin doesn’t 
depend on the depth of the laser pores in the dermis as long as the epidermis is penetrated.28 The 
pulse energy of the CO2-laser used here, 84 mJ, corresponds to a channel in the skin that is 
approximately 200 μm deep (measured histologically from a skin biopsy of a healthy volunteer in 
Päijät-Häme Central Hospital, data not shown) which would be sufficient for full penetration of the 
epidermis, which is less than 100 μm thick except in the palms of the hands.29 
 
The failure rate of AFL-assisted PDT, i.e. the number of histopathological LM residives observed, 
was 3 out of 10 LM lesions (30%), whereas the reported recurrence rates for the standard surgical 
excision of LMs are in the range of 8–20% (mean 6.8% at 5 years), those for staged excision 0–7%, 
and those for Mohs micrographic surgery 0–2%.12,30 In a recent review of non-surgical treatments 
available for LM the recurrence rates were 0–31% (mean 11.5%) for radiotherapy, 4–50% (mean 
24.5%) for imiquimod and 0–100% (mean 34.4%) for laser therapy, which are all inferior to those 
achieved with surgical methods.14 The cure rate in our present pilot study is superior to that for laser 
therapy, in line with imiquimod, but inferior to radiotherapy. A high recurrence rate with any 
treatment modality may be derived from deep follicular extension, unsuspected invasion or 
subclinical extension of the LM.12 Among our three non-responders, one LM was located on the 
cheek (Figure 3) and the histopathological evaluation after PDT revealed lentigo maligna with a 1 
mm deep follicular extension, so that the accumulation of protoporphyrin in the deep part of the 
lesion may not have been sufficient, which could explain the failure of PDT in this case. Otherwise, 
no correlation between demographic data or lesion baseline characteristics and histologic outcome 
could be found which is most likely due to small sample size. 
 
The limitations of our study were: the small number of cases, due to the piloting nature of the study; 
the duration of adverse skin reactions was not recorded; and the use of the routine bread-loaf 
technique in the histological assessment of the lesions which could have caused us to miss some 
residual part of a lesion.31 This must partly have been offset, however, by the fact that the lesions 
were completely excised with 5 mm margins after the treatment. A strength of this work lies in the 
fact that it is the first prospective study assessing the effect of AFL-assisted PDT in the treatment of 
LM, offering a basis for future larger studies.  
 
11 
 
 
 
In conclusion, the present results demonstrate that ablative fractional laser-assisted PDT is an 
alternative effective option for treating lentigo maligna. Histopathological assessment of the wide 
excision specimens showed that 7 out of the 10 lesions (70%) were histologically completely 
cleared after three AFL-assisted PDT sessions. The patient-reported pain during PDT illumination 
was moderate and tolerable, although a few severe skin reactions were observed after the PDT. 
AFL-assisted PDT could be considered as a treatment option for non-invasive lentigo maligna in 
patients for whom surgery is contraindicated or as a second-line treatment for residual lesions. 
Further studies with larger samples are warranted to confirm these preliminary results. 
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Tables 
 
Table 1. Patient demographics and baseline characteristics of the lentigo malignas included in the 
series. *) Patient 9 had two lentigo malignas. AK = actinic keratosis, BCC = basal cell carcinoma, 
DN = dysplastic nevus, LM = lentigo maligna, LMM = lentigo maligna melanoma, MM = 
malignant melanoma, SCC = squamous cell carcinoma. 
Patient Gender 
(M/F) 
Age 
(y) 
Skin 
photo-
type 
Previous 
skin cancers 
LM 
lesion 
Location Lesion 
size 
(mm) 
Lesion 
area 
(mm
2
) 
Lesion 
histologically 
cleared (Y/N) 
1 M 69 II AK 1 forehead 8 x 10 63 No 
2 M 83 II - 2 cheek 14 x 21 231 No 
3 M 62 II BCC, SCC, 
DN x 2, MM 
x 2, LM x 2,  
3 forearm 10 x 17 134 Yes 
4 M 71 I AK 4 upper back 12 x 13 123 Yes 
5 M 75 II - 5 upper 
thorax 
11 x 13 112 Yes 
6 F 77 II - 6 forearm 9 x 12 84 No 
7 M 77 II AK, Mb 
Bowen, BCC 
7 cheek 10 x 14 110 Yes 
8 F 71 II BCC, LMM 8 lower back 6 x 8 38 Yes 
9 M 79 III AK, kerato-
acanthoma 
9* temple 8 x 8 50 Yes 
9     10* neck 6 x 8 38 Yes 
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Table 2. Clinical response, dermoscopy and histological clearance of the lentigo malignas four 
weeks after the last photodynamic therapy. *) LM 9 and 10 belonged to the same patient. IHC = 
immunohistochemistry, LM = lentigo maligna. 
LM 
lesion 
Clinical response  Dermoscopy Histopathological 
findings in excision 
specimens 
IHC used Lesion 
histologically 
cleared (Y/N) 
1 No visible pigment White streaks, erythema Atypical melanocyte 
proliferation/ lentigo 
maligna suspicion  
- No 
2 Small pigmented 
area 
Pigment network, 
erythema 
Lentigo maligna - No 
3 No visible pigment White streaks, erythema Scar and perivascular 
inflammation 
- Yes 
4 No visible pigment White streaks, erythema Scar - Yes 
5 Almost invisible 
pigmentation 
Light diffuse 
pigmentation, erythema 
Scar - Yes 
6 Some pigmentation 
left, bleached 
- Lentigo maligna - No 
7 Small pigmented 
area, mostly 
invisible 
Small area of diffuse 
pigmentation, white 
streaks, erythema 
Scar - Yes 
8 Small pigmented 
dot in the middle 
Small pigmented dot in 
the middle, erythema 
Benign lentigo, 
fibrosis and 
inflammation 
MART1, 
elastin 
Yes 
9* No visible pigment Erythema Solar elastosis MART1 Yes 
10* No visible pigment Erythema Scar and solar elastosis MART1, 
Fontana 
Yes 
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Table 3. Pain visual assessment scores (VAS) during the PDT illumination and the skin reaction 
two days after the 1st PDT session. *) LM 9 and 10 belonged to the same patient. LM = lentigo 
maligna, PDT = photodynamic therapy, SD = standard deviation. 
LM 
lesion 
Location PDT 1 
Max. pain 
(VAS 0–10) 
PDT 2 
Max. pain 
(VAS 0–10) 
PDT 3 
Max. pain 
(VAS 0–10) 
Skin reaction 
2 days after 
PDT 1 (0–4) 
Notes 
1 forehead 1.8 4.4 2.2 4 After the excision a constant 
stinging pain occurred in the 
excised area. The pain 
ceased after a second 
excision for margin control. 
2 cheek 0 0.1 1.2 2 A very intense skin reaction 
with erythema, swelling and 
burning pain after the 3rd 
PDT session. 
3 forearm 0.9 5 2.3 4 - 
4 upper back 2.3 1.4 1.8 4 - 
5 upper 
thorax 
5.4 6.5 3.7 3 Moderate pain continued for 
several hours after the 2nd 
PDT session. 
6 forearm 4 4.4 1.6 3 Moderate pain continued for 
several hours after the 2nd 
PDT session. 
7 cheek 2.2 1.4 1.5 3 Skin swelling of the eyelid 
and the neck after the 2nd 
PDT session. 
8 lower back 4.4 4.7 5.5 4 A very intense skin reaction 
with violaceous erythema 
and abundant secretion after 
the 2nd PDT session. 
9* temple 5 5.1 4.3 2 - 
10* neck 5 5.3 5.1 3 - 
 Mean ± SD 3.1 ± 1.9 3.8 ± 2.1 2.9 ± 1.6 3.3 ± 0.7  
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Figures 
 
 
Figure 1. Flow-chart of the protocol. The histological diagnoses of the biopsied lesions were: 11 
LM, 2 LMM, 1 other MM, 1 lentigo, 2 seborrhoeic keratoses, 3 postinflammatory 
hyperpigmentation, 6 pigmented actinic keratosis, 6 dysplastic nevi. *) One lentigo maligna was 
excluded after biopsy because of difficulties in scheduling the PDT treatments according to the 
study protocol. LM = lentigo maligna, LMM = lentigo maligna melanoma, MM = malignant 
melanoma. 
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Figure 2. Clinical, dermoscopic and histological images of a cured lentigo maligna (LM) before 
and after photodynamic therapy (PDT). (a) Photograph of a LM located on the chest before PDT, 
(b) photograph four weeks after the last PDT treatment, (c) dermoscopic image before PDT, (d) 
dermoscopic image after PDT shows no visible pigmentation, (e) histology before PDT shows 
confluent atypical melanocyte proliferation at the junction, (f) histology after PDT shows scar 
formation in the dermis with no sign of atypical melanocytes. Magnification 20X. 
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Figure 3. Clinical, dermoscopic and histological images of a non-responding lentigo maligna (LM) 
before and after photodynamic therapy (PDT). (a) Photograph of a LM located on the cheek before 
PDT, (b) photograph of the residual LM four weeks after the last PDT treatment, (c) dermoscopic 
image before PDT, (d) dermoscopic image after PDT, showing a residual pigment network, 
erythema and white streaks, (e) histology before PDT, shows islands of atypical melanocytes with 
poor cohesion and atypical melanocyte proliferation at the junction, (f) histology after PDT, 
showing lentiginous proliferation of atypical melanocytes with variations in cell shape and size. 
Magnification 20X. 
